Top news of the week: 19.01.2022.
Companies And Industries
Novel Vaccines with Novel Targets Emerge at Biotech Showcase
Vaccine development is experiencing a resurgence in the wake of the COVID-19 pandemic, with companies developing a variety of approaches.
Sarepta, with pivotal data in sight, dumps Lysogene gene therapy
Sarepta Therapeutics is walking away from a partnered gene therapy just months before the readout of a pivotal clinical trial. The biotech stuck with Lysogene through a tough 2020 that ...
JPM Day 4: Battered Emergent Solutions Looks Ahead, Vir and Thermo Fisher
Emergent BioSolutions, Vir Biotechnology and Thermo Fisher, comes into 2022 with reports of new opportunities, new vaccines, and partnership expansions.
Single Cell RNA-Seq and Spatial Data Merge Using Cell2location
Comprehensive cellular maps of tissues enabled by a new tool, сell2location, combines scRNA-seq data with spatial information.
FDA denies Denali's Takeda-partnered Alzheimer's drug from entering clinic
The FDA has thrown Denali Therapeutics' Alzheimer's med into murky waters with a clinical hold before the drug even enters human trials. The move also impacts Takeda, which just last month ...
FDA approval, global partnership on the agenda at Mithra as phase 3 menopause trials hit goals—with one blemish
Mithra has brushed off a missed co-primary endpoint in one of its two phase 3 clinical trials and given a bullish update on the menopause drug, which it expects to gain a global partner ...
JPM22, Day 4: Vertex aims to be cystic fibrosis leader into the 2030s; Gritstone hopes for new colorectal cancer biomarker
Join us for a rolling look at the top life science news coming out of this year's virtual J.P. Morgan Healthcare Conference.
With $3 billion, biotech veterans launch a global company aimed at disease ‘reversal’
With $3 billion, some of the biggest names in biotech are launching a global company aimed at disease "reversal."